The tweet was deleted by the author.
But we saved everything 🙂.
Humacyte presented a clinical case report highlighting the use of a bioengineered human acellular vessel in reconstructing an infected vascular site.
The case was delivered by Rishi Kundi, MD during Session 3: Lower Extremity Arterial – Part 1, aiming to address complex surgical scenarios where infection complicates vessel repair.
View post on X Loading...
Humacyte has previously presented interim Phase 3 V012 results on its acellular tissue-engineered vessel (ATEV) for hemodialysis access in women at Kidney Week, according to company disclosures. The company also released long-term clinical data indicating that the ATEV vessel showed low susceptibility to atherosclerosis in 52 patients, as reported in earlier findings. These prior updates provide context for Humacyte’s ongoing clinical initiatives in vascular reconstruction.